## **Listing of Claims:**

- (Original) An isolated nucleotide sequence having a nucleotide sequence having at least about 50% sequence homology with a sequence that is a truncated form of SEQ ID No. 8.
- 2. (Original) The sequence of claim 1, said sequence having at least about 60% sequence homology with a sequence selected from the group consisting of SEQ ID Nos. 8-14.
- 3. (Original) The sequence of claim 1, said sequence having at least about 75% sequence homology with a sequence selected from the group consisting of SEQ ID Nos. 8-14.
- 4. (Original) The sequence of claim 1, said sequence having at least about 87% sequence homology with a sequence selected from the group consisting of SEQ ID Nos. 8-14.
- 5. (Original) The sequence of claim 1, said sequence having at least about 95% sequence homology with a sequence selected from the group consisting of SEQ ID Nos. 8-14.
- 6. (Original) An expression vector containing a nucleotide sequence having at least about 50% sequence homology with a truncated sequence from SEQ ID No. 8.

- 7. (Original) The vector of claim 6, said nucleotide sequence having at least about 60% sequence homology with a sequence selected from the group consisting of SEQ ID Nos. 8-14.
- 8. (Original) The vector of claim 6, said nucleotide sequence having at least about 75% sequence homology with a sequence selected from the group consisting of SEQ ID Nos. 8-14.
- 9. (Original) The vector of claim 6, said nucleotide sequence having at least about 87% sequence homology with a sequence selected from the group consisting of SEQ ID Nos. 8-14.
- 10. (Original) The vector of claim 6, said nucleotide sequence having at least about 95% sequence homology with a sequence selected from the group consisting of SEQ ID Nos. 8-14.
- 11. (Original) An isolated nucleotide sequence which differs from that of claim 1 due to a mutation event selected from the group consisting of point mutations, deletions, insertions and rearrangements.

- 12. (Withdrawn) A vaccine effective for conferring protective immunity against *F. necrophorum* comprising the protein expressed by a portion of SEQ ID No. 8 and a suitable pharmacologically compatible carrier.
- 13. (Withdrawn) The vaccine of claim 12, said vaccine being prepared by a method comprising the steps of:
  - a) providing the F. necrophorum gene which expresses leukotoxin;
  - b) truncating said *F. necrophorum* gene into a plurality of discrete nucleotide sequences, each of said discrete nucleotide sequences encoding for a respective polypeptide sequence;
  - c) expressing and recovering said encoded polypeptide sequence expressed by at least one
    of said discrete nucleotide sequences;
  - d) inactivating said recovered polypeptide sequence; and
  - e) combining said inactivated polypeptide sequence with said suitable pharmacologically compatible carrier to produce said vaccine.
- 14. (Withdrawn) The vaccine of claim 13, said discrete nucleotide sequences having a sequence having at least about 50% sequence homology with a sequence selected from the group consisting of SEQ ID Nos. 9-14.

Serial No. 10/647,057

Docket No. 30296A-DIV1

- 15. (Withdrawn) The vaccine of claim 13, further comprising the step of expressing and recovering said respective polypeptides using said nucleotide.
- 16. (Original) A recombinantly derived nucleotide sequence than encodes a polypeptide effective in conferring protective immunity against *F. necrophorum* infection in mice, said sequence comprising a truncated form of SEQ ID No. 8.
- 17. (Original) The sequence of claim 16, said sequence having at least about 50% sequence homology with a sequence selected from SEQ ID Nos. 9- 14.